Camatinib (Tabrecta) is a targeted therapeutic drug that has shown good efficacy in the treatment of specific types of non-small cell lung cancer (NSCLC) in recent years. As a kinase inhibitor, it exerts its anti-cancer effect by precisely acting on MET gene mutations.
How Effective is Camatinib (Tabrecta) in Treatment?
Therapeutic Efficacy
Camatinib has demonstrated favorable therapeutic activity in patients with metastatic non-small cell lung cancer (NSCLC) who test positive for MET exon 14 skipping mutation.
By specifically inhibiting the activity of MET receptor tyrosine kinase, the drug blocks the transmission of downstream signaling pathways, thereby inhibiting the proliferation and survival of tumor cells.
Population Eligible for Camatinib (Tabrecta) Treatment
Requirements for Patient Status
Eligible patients should be adults, and their disease should be in the metastatic stage.
Prior to the use of the drug, the presence of the mutation must be confirmed through professional genetic testing—this is a crucial prerequisite for ensuring treatment efficacy.
The drug has shown efficacy in both treatment-naive patients (patients who have not received prior treatment) and pre-treated patients (patients who have received previous treatment). However, the specific treatment plan needs to be formulated based on the individual conditions of the patients.
Precautions for Special Populations
For elderly patients, dose adjustment is generally not required, but close monitoring is necessary.
Patients with hepatic or renal impairment also require special attention. In particular, there is limited experience in the use of this drug in patients with severe renal impairment, so a cautious assessment should be conducted.
The drug is contraindicated in pregnant women. Men and women of childbearing age must take effective contraceptive measures during the medication period and for a certain period after discontinuing the drug.
Medication Monitoring for Camatinib (Tabrecta)
Efficacy Monitoring
Regular imaging examinations to assess tumor changes are the main method for monitoring therapeutic efficacy.
Pay attention to changes in patients' symptoms, such as the improvement of symptoms like dyspnea and cough.
The patient's overall functional status and quality of life are also important indicators for evaluating therapeutic efficacy.
Safety Monitoring
Pulmonary Monitoring: Vigilance is required for the occurrence of interstitial lung disease (ILD)/pneumonitis. Once new or worsening pulmonary symptoms appear, the patient should seek medical attention immediately for evaluation.
Hepatic Function Monitoring: It is necessary to conduct regular hepatic function tests before and during treatment, with more frequent monitoring especially in the first 3 months.
Other Monitoring: This includes routine indicators such as renal function and electrolyte balance, as well as other adverse reactions that may be caused by the drug.
